BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 25064744)

  • 21. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
    Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
    Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in the clinical impact of high-risk human leukocyte antigen allele mismatch combinations on the outcome of unrelated bone marrow transplantation.
    Kanda Y; Kanda J; Atsuta Y; Fuji S; Maeda Y; Ichinohe T; Takanashi M; Ohashi K; Fukuda T; Miyamura K; Mori T; Sao H; Kobayashi N; Iwato K; Sawada A; Mori S;
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):526-35. PubMed ID: 24417871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HLA-DPB1 and DPA1 ~ DPB1 linkage mismatch affects the survival of recipients receiving HLA-14/14 matched unrelated donor HSCT.
    Liu S; Zhang T; Wu X; Yuan X; Zhu W; Chen L; Jiang X; Yang T; Li Y; Wang L; Gong Y; Wu D; Bao X; He J
    HLA; 2024 Jun; 103(6):e15542. PubMed ID: 38887889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
    Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
    Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Analysis.
    Mytilineos D; Tsamadou C; Neuchel C; Platzbecker U; Bunjes D; Schub N; Wagner-Drouet E; Wulf G; Kröger N; Murawski N; Einsele H; Schaefer-Eckart K; Freitag S; Casper J; Kaufmann M; Dürholt M; Hertenstein B; Klein S; Ringhoffer M; Mueller CR; Frank S; Schrezenmeier H; Fuerst D; Mytilineos J
    Front Immunol; 2020; 11():614976. PubMed ID: 33569061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suggestive evidence of a role of HLA-DRB4 mismatches in the outcome of allogeneic hematopoietic stem cell transplantation with HLA-10/10-matched unrelated donors: a French-Swiss retrospective study.
    Detrait M; Morisset S; Chalandon Y; Yakoub-Agha I; Dufossé F; Labalette M; Top I; Elsermans V; Barraco F; Quintela A; Tedone N; Michallet M; Raus N; Tiercy JM; Dubois V
    Bone Marrow Transplant; 2015 Oct; 50(10):1316-20. PubMed ID: 26146803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1.
    Fleischhauer K; Fernandez-Viña MA; Wang T; Haagenson M; Battiwalla M; Baxter-Lowe LA; Ciceri F; Dehn J; Gajewski J; Hale GA; Heemskerk MB; Marino SR; McCarthy PL; Miklos D; Oudshoorn M; Pollack MS; Reddy V; Senitzer D; Shaw BE; Waller EK; Lee SJ; Spellman SR
    Bone Marrow Transplant; 2014 Sep; 49(9):1176-83. PubMed ID: 24955785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High resolution HLA class I and II typing and CTLp frequency in unrelated donor transplantation: a single-institution retrospective study of 69 BMTs.
    El Kassar N; Legouvello S; Joseph CM; Salesses P; Rieux C; Cordonnier C; Vernant JP; Farcet JP; Bierling P; Kuentz M
    Bone Marrow Transplant; 2001 Jan; 27(1):35-43. PubMed ID: 11244436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation.
    Rockstroh A; Al-Ali HK; Lange T; Pönisch W; Krahl R; Cross M; Behre G; Niederwieser D; Pfrepper C
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2193-203. PubMed ID: 26129640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of HLA mismatch direction on the outcome of unrelated bone marrow transplantation: a retrospective analysis from the Japan Society for Hematopoietic Cell Transplantation.
    Kanda J; Ichinohe T; Fuji S; Maeda Y; Ohashi K; Fukuda T; Miyamura K; Iwato K; Eto T; Nakamae H; Kobayashi N; Mori T; Mori S; Morishima Y; Atsuta Y; Kanda Y;
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):305-11. PubMed ID: 25464119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy.
    Yakoub-Agha I; Mesnil F; Kuentz M; Boiron JM; Ifrah N; Milpied N; Chehata S; Esperou H; Vernant JP; Michallet M; Buzyn A; Gratecos N; Cahn JY; Bourhis JH; Chir Z; Raffoux C; Socié G; Golmard JL; Jouet JP;
    J Clin Oncol; 2006 Dec; 24(36):5695-702. PubMed ID: 17116940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease.
    Parmar S; Del Lima M; Zou Y; Patah PA; Liu P; Cano P; Rondon G; Pesoa S; de Padua Silva L; Qazilbash MH; Hosing C; Popat U; Kebriaei P; Shpall EJ; Giralt S; Champlin RE; Stastny P; Fernandez-Vina M
    Blood; 2009 Oct; 114(14):2884-7. PubMed ID: 19654407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High HLA-DP Expression and Graft-versus-Host Disease.
    Petersdorf EW; Malkki M; O'hUigin C; Carrington M; Gooley T; Haagenson MD; Horowitz MM; Spellman SR; Wang T; Stevenson P
    N Engl J Med; 2015 Aug; 373(7):599-609. PubMed ID: 26267621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease.
    Huang XJ; Han W; Xu LP; Chen YH; Liu DH; Lu J; Chen H; Zhang YC; Jiang Q; Liu KY; Lu DP
    Chin Med J (Engl); 2004 Dec; 117(12):1778-85. PubMed ID: 15603704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
    Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
    Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.
    Larsen ME; Kornblit B; Larsen MV; Masmas TN; Nielsen M; Thiim M; Garred P; Stryhn A; Lund O; Buus S; Vindelov L
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1370-81. PubMed ID: 20353833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular disparity of HLA-DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation.
    Zou J; Kongtim P; Oran B; Srour SA; Greenbaum U; Carmazzi Y; Rondon G; Ciurea SO; Ma Q; Shpall EJ; Champlin RE; Cao K
    Cancer; 2023 Apr; 129(8):1205-1216. PubMed ID: 36738229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.